SOFIA (Bulgaria), August 8 (SeeNews) - Bulgarian pharmaceuticals producer Sopharma [BUL:SFA] said that its sales revenue surged 146% on the year in July on the back of a 206% jump in exports.
Sopharma's domestic sales also recorded a strong annual growth, adding 96% year-on-year, the company said in a stock exchange filing on Friday.
Sopharma's sales revenue in the first seven months of 2022 was 46% higher compared to the same period of 2021, as domestic sales grew by 42% year-on-year, while exports increased by 49%.
Last week, Sopharma said that it standalone net profit went up to 23.6 million levs ($12.3 million/12.1 million euro) in the first half of 2022 from just over 12 million levs a year earlier, after revenue ticked up by 35% on the year to 116.9 million levs.
Shares in Sopharma closed flat at 4.48 levs in its most recent trading session on the stock exchange in Sofia on Friday.
(1 euro = 1.95583 levs)